Structure Therapeutics (GPCR) Research & Development (2022 - 2026)

Structure Therapeutics' Research & Development history runs 5 years deep, the most recent figure standing at $66.5 million for Q1 2026.

• In Q1 2026, Research & Development rose 55.15% year-over-year to $66.5 million; the TTM figure through Mar 2026 stood at $248.9 million (up 89.99% YoY), while the FY2025 annual figure was $225.3 million, up 107.01% from the prior year.
• Research & Development for Q1 2026 stood at $66.5 million, down from $68.7 million in the prior quarter.
• The five-year high for Research & Development was $68.7 million in Q4 2025, with the low at $8.4 million in Q4 2022.
• The 5-year median for Research & Development is $20.7 million (2024), against an average of $29.8 million.
• The sharpest annual moves came in 2024 and 2025: Research & Development gained 13.6% in 2024, then jumped 148.12% in 2025.
• Structure Therapeutics' Research & Development stood at $8.4 million in 2022, then surged by 139.74% to $20.0 million in 2023, then soared by 67.08% to $33.5 million in 2024, then jumped by 105.12% to $68.7 million in 2025, then declined by 3.18% to $66.5 million in 2026.
• Business Quant data shows GPCR's Research & Development at $66.5 million in Q1 2026, $68.7 million in Q4 2025, and $59.0 million in Q3 2025.